Canadian urological association

The Canadian Urological Association CUA does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals.

Federal government websites often end in. The site is secure. Prostate cancer remains the most commonly diagnosed non-cutaneous malignancy among Canadian men and is the third leading cause of cancer-related death. In , an estimated 21 men were diagnosed with prostate cancer and men died from the disease; 1 however, prostate cancer is a heterogeneous disease with a clinical course ranging from indolent to life-threatening. Identifying and treating men with clinically significant prostate cancer while avoiding the over-diagnosis and over-treatment of indolent disease remains a significant challenge. Several professional associations have developed guidelines on prostate cancer screening and early diagnosis, but there are conflicting recommendations on how best to approach these issues.

Canadian urological association

McMaster Institute of Urology at St. Published: Robotic-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction A retrospective review of a high-volume Canadian center Michael Ordon, Aren Mnatzakanian, Melody Djuimo, R. Vangala, Mohammed Bassuony, Ahmed S. Zakaria, Walid Shahrour, Hazem Elmansy. High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experience Hanbo Zhang, Nimira S. Alimohamed, Naveen S. Stenson, Douglas A. Stewart, Christopher P. Venner, Peter Venner, Michael P. Complication rates of ciprofloxacin alone vs. Prognostic model using postoperative normalization of C-reactive protein levels in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy Jun Teishima, Junichiro Hirata, Takuya Toge, Riku Uematsu, Yoshie Mita, Takahiko Yoshii, Ichiro Nakamura. Sfakianos, Tracy L. Zlotta, Brant Inman, Peter C. Poon, James T.

The CUA has eight categories of membership. Men undergoing screening should be involved in the decision-making regarding prostate biopsy.

Full-length guidelines are reserved for broader topics that require more comprehensive exploration. BPRs provide a more focused, concise summary of the best evidence available on common urological topics to help guide management decisions. Both formats have undergone official CUA guideline approval process. Reproduction of any part of the published CUA guidelines, consensus statements, and best practice reports requires the express written consent of the Canadian Urological Association CUA. McMaster Institute of Urology at St.

Federal government websites often end in. The site is secure. Preview improvements coming to the PMC website in October Learn More or Try it out now. It is well-described that neurological disorders can lead to urological complications, including: urinary incontinence, urinary tract infections UTIs , urolithiasis, sepsis, ureteric obstruction, vesicoureteric reflux VUR , and renal failure.

Canadian urological association

Federal government websites often end in. The site is secure. Preview improvements coming to the PMC website in October Learn More or Try it out now. Prostate cancer remains the most commonly diagnosed non-cutaneous malignancy among Canadian men and is the third leading cause of cancer-related death. In , an estimated 21 men were diagnosed with prostate cancer and men died from the disease; 1 however, prostate cancer is a heterogeneous disease with a clinical course ranging from indolent to life-threatening. Identifying and treating men with clinically significant prostate cancer while avoiding the over-diagnosis and over-treatment of indolent disease remains a significant challenge.

Husvjjal2 onlyfans leak

In order to develop these recommendations, the following questions related to prostate cancer screening and diagnosis were defined, a priori, to guide the specific literature searches and evidence synthesis:. Percent free PSA The measurement of percent free PSA has been studied as a risk-stratifying tool aimed at distinguishing men at risk from prostate cancer vs. It was felt a more comprehensive sampling was needed to better understand contemporary demographics and practice patterns. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. Additionally, a single PSA measurement should not be used to guide biopsy decision-making. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective, multicenter clinical trial. Recommendations on screening for prostate cancer with the prostate-specific antigen test. The test has been validated in several subsequent studies evaluating previously screened men, unscreened men, and men with a prior negative biopsy 66 , 67 , 69 — 72 area under the curve [AUC] of 0. Pre-contacting participants and using methods other than online platforms also enhanced response rates, while use of incentives does not appear to impart much added benefit. Participants practicing in Quebec and the Prairie provinces reported higher rates of difficulty than other regions. Zakaria, Walid Shahrour, Hazem Elmansy.

The Canadian Urological Association CUA does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals.

Supplementary Information Click here to view. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. Comp Hum Behav Rep. Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: A Cancer Care Ontario updated clinical practice guideline. Zlotta, Brant Inman, Peter C. Census surveys rely on individuals self-reporting and, therefore, the responses cannot be validated and are potentially subject to bias. When prostate cancer screening is performed, the overarching goal should be the early detection of clinically significant prostate cancer in healthy men while minimizing the detection and treatment of low-risk disease. Recommendations on screening for prostate cancer with the prostate-specific antigen test. Biomarkers 1. Bruno Laroche. Although various single PSA thresholds, as well as age- 96 — 98 and race-specific 96 , 99 PSA thresholds have been proposed for biopsy decision-making, no uniform cutoff for PSA can be recommended for all men.